Top Tweets for #Checkmate214
#CheckMate214 final overall survival data: Long-term survival benefits of ipi/nivo in #KidneyCancer. @MikeSerzanMD @DanaFarber joins @PBarataMD @caseccc to discuss data demonstrating maintained OS benefit in intermediate- and poor-risk patients with over eight years follow-up, showing 20-30% plateaus on survival curves. #WatchNow > https://t.co/5EBnLM44Tp
#CheckMate214 final overall survival data: Long-term survival benefits of ipi/nivo in #KidneyCancer. @MikeSerzanMD @DanaFarber joins @PBarataMD @caseccc to discuss data demonstrating maintained OS benefit in intermediate- and poor-risk patients with over eight years follow-up, showing 20-30% plateaus on survival curves. #WatchNow > https://t.co/5EBnLM44Tp
#CheckMate214 final overall survival data: Long-term survival benefits of ipi/nivo in #KidneyCancer. @MikeSerzanMD @DanaFarber joins @PBarataMD @caseccc to discuss data demonstrating maintained OS benefit in intermediate- and poor-risk patients with over eight years follow-up, showing 20-30% plateaus on survival curves. #WatchNow > https://t.co/5EBnLM44Tp
@ZakhariaYousef @cityofhope gives #BestofASCO updates in #kidneycancer and #bladdercancer. Excellent overviews of #Checkmate214 ipi-nivo for RCC, #Keynote564 adjuvant pembro for RCC, #EV302 for EV-pembro for bladder, and #NIAGARA ctDNA analysis! Great seeing him in Dallas!
Nivolumab + Ipilimumab vs sunitinib for first-line treatment of advanced #RenalCellCarcinoma: #FinalAnalysis from the phase 3 #CheckMate214 trial. Presentation by @motzermd @MSKCancerCenter. #ASCO25 written coverage by @RKSayyid @USC > https://t.co/i2q2MImdHs @ASCO
🗣️Kidney Cancer Oral Abstracts #ASCO25
👉Abs4505: Dr @motzermd presenting 9⃣yr f/u Nivo/Ipi vs Sunitinib for 1L ccRCC #CheckMate214
ITT (n = 1096)
♦️96 mo PFS rate = (23% vs 9%)
♦️96 mo DOR rate = (48% vs 19%)
♦️108 mo OS rate = (31% vs 20%)
♦️mOS (53mo vs 38mo) (HR 0.71)
INT/POOR risk (n = 847)
♦️96 mo PFS rate = (25% vs 9%)
♦️96 mo PFS rate = (50% vs 23%)
♦️108 mo OS rate = (30% vs 19%)
♦️mOS (47mo vs 26mo) (HR 0.69)
FAV risk (n = 847)
♦️96 mo PFS rate = (13% vs 11%)
♦️96 mo DOR rate = (36% vs NA)
♦️108 mo OS rate = (35% vs 22%)
♦️mOS (78mo vs 67mo) (HR 0.80)
🩺KEY TAKE AWAYS
- Nivo/Ipi a/w long term durable responses in ITT w/plateaus in PFS (23%) and OS (31%) curves and median DOR (76.2mo vs 25.1mo)
- FAV risk OS improved from 1.45 (2018) to 0.80 (2025) suggesting long-term benefit of induction IO regimen
❓ How to we #RaiseTheTail leading to more cures?
Ongoing 1L ccRCC Studies
✨#PEDIGREE Adaptive Sequential Therapy
✨#OPTIC Cluster Selected IO/IO vs IO/TKI
✨#CURE1 PD1 Selected IO/IO vs IO/TKI
✨#ARCITECT novel CTLA #Botensilimab
👥@DrChoueiri @ERPlimackMD @TiansterZhang @DrRanaMcKay @tompowles1 @brian_rini @BraunMDPhD @HHammersMD @PBarataMD @PavlosMsaouel @yekeduz_emre @DrYukselUrun @ReneeSaliby @drenriquegrande @bavilima @DRBakaloudiMD @ReginaBarCar @crisbergerot @kidneycan @KidneyCancer @ASCO
Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced #RenalCellCarcinoma: Post-hoc analysis of #CheckMate214. Presentation by @VincentWenxinXu @DanaFarber > https://t.co/CwAVHj9GqF @ASCO
🔥 New from #GU25! Dr. Wenxin Xu presents post-hoc #CheckMate214 analysis:
📉 Early KIM-1 drop (3 wks) w/ Nivo+Ipi predicts long-term efficacy
⚠️ High baseline KIM-1 = worse OS/PFS
🔬 Prospective trials needed to confirm KIM-1 as a biomarker for IO response! 🚀
🖋️:@hjwang26
What is KIM-1 (kidney injury molecule) & it’s role as a prognostic/predictive biomarker in RCC? Analysis of KIM-1 in #CheckMate214 of ipi/nivo vs sunitinib @ASCO #GU25
KIM-1 is transmembrane protein over-expressed in ccRCC and emerging biomarker...
Key Takeaways, in CheckMate214:
✅Early decrease in serum KIM-1 at 3w after nivo/ipi is associated with long term efficacy (not sunitinib arm)
📌Higher baseline KIM-1 has worse outcomes in patients and a higher tumor burden
📌Higher KIM-1 associated with worse IMDC risk and no prior nephrectomy
🔎Circulating KIM-1 should be evaluated in prospective trials as early biomarker for response to IO in RCC
@OncoAlert @GUOncologyNow @urotoday @TargetedOnc @OncoReporte @OncLive @kidneycan @KidneyCancer
.@DrJeffreyGraham reviewing 8-year follow-up data and OS rates from #CheckMate214 study of patients with advanced renal-cell carcinoma. Watch his full session here: https://t.co/BVNaEjiwaJ
#KidneyCancer #MedOnc
📅 March is #KidneyCancerAwarenessMonth.
📺 In our latest video, @Daniel_J_George of @DukeCancer, @DukeHealth, shares his expert opinion on the 8-year #CheckMate214 survival and durable response data for advanced #KidneyCancer.
🎥 Watch Now: https://t.co/upsyJybYfw
Nivolumab + ipilimumab vs sunitinib for first-line treatment of advanced #RCC: long-term follow-up data from the phase 3 #CheckMate214 trial. Presented by Nizar Tannir, MD, FACP @MDAndersonNews. #GU24 written coverage by @zklaassen_md @GACancerCenter > https://t.co/6SlLdyaW8V
#NizarTannir & @bmsnews team with true dedication to the study follow-up of #Checkmate214 — 8 year data and moving the needle in favorable risk #kidneycancer. Ipi-nivo should be considered when shooting for durable response and long term survival benefit. @ASCO #GU24 @OncoAlert
4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter
Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214
4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter
Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214
4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter
Let’s revisit efficacy of🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214
13/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter
🔬Common tox in pivotal P3 #CHECKMATE214 trial of dual ICI combo🔬
🔸Fatigue
🔹Pruritus
🔸Diarrhea
🔹Rash
🔸Nausea
6/ #TumorBoardTuesday #BonumCE #OncTwitter #NephTwitter #MedTwitter #RenalCell
✳️Dual ICI combo (ipi + nivo) also approved tx option
💎#CheckMate214 - ipi + nivo vs sunitinib
✅Longest follow-up in frontline RCC (>5 years)
✅OS and PFS favor combo tx in int/poor risk pts
5/#TumorBoardTuesday #RenalCell
🔑Ph3 trls #KEYNOTE426, #CLEAR, #CheckMate9ER, #CheckMate214
💎Each combo regimen ⬆️PFS, OS, & ORR vs sunitinib
💎Axi-avelumab approved but OS data immature
💎Benefit across IMDC risk groups
💎Axi-pembro=longest f/u among approved TKI-ICI in RCC
5/#TumorBoardTuesday #RenalCell
🔑Ph3 trls #KEYNOTE426, #CLEAR, #CheckMate9ER, #CheckMate214
💎Each combo regimen ⬆️PFS, OS, & ORR vs sunitinib
💎Axi-avelumab approved but OS data immature
💎Benefit across IMDC risk groups
💎Axi-pembro=longest f/u among approved TKI-ICI in RCC
Last Seen Hashtags on Sotwe
pinaycumtribute
Seen from Philippines
اونلي_فانز
Seen from United Kingdom
popupfoodfridays
Seen from United States
Teenagegirls()
Seen from Poland
gustirandaout
Seen from United States
nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit #nolimit
Seen from Turkey
valeng222
Seen from Colombia
Flaky
Seen from United States
xlii #exny #nolimit() +filter:native_video
Seen from Turkey
freaks
Seen from South Africa
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.6M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.2M followers
Taylor Swift
@taylorswift13
82M followers
Lady Gaga
@ladygaga
73.6M followers
Virat Kohli
@imvkohli
70.7M followers
Kim Kardashian
@kimkardashian
70M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.2M followers
Neymar Jr
@neymarjr
63.6M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
61.3M followers
X
@x
60.8M followers